Biohaven
Company

Last deal

$230.M

Amount

Post-IPO Equity

Stage

18.04.2024

Date

2

all rounds

$455.M

Total amount

General

About Company
Biohaven is a biopharmaceutical firm focused on unearthing and creating treatments for severe illnesses.

Industry

Sector :

Subsector :

Also Known As

Biohaven Research Ltd.

founded date

2013

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contacts

Social url